Issues & Trends

[Exclusive] MBK Completes Voluntary Cancellation of All Homeplus Common Stock Worth 2.5 Trillion Won

Completed the cancellation of all 2.4 million shares last month Actual Implementation Follows Approval of Restructuring Plan Burden on Buyers Eased… Expectations for Stronger Sales Momentum

Hur Jieun
2026-10-07 08:39:02
[Photo: Newsis]
[Edaily Marketin Reporter Hur Jieun ] It has been confirmed that MBK Partners, the major shareholder of Homeplus, canceled all of its common stock holdings—worth 2.5 trillion won—last month without compensation. This cancellation was a measure that MBK had publicly announced several times since the early stages of the reorganization proceedings, and it appears to have been carried out following the approval of the reorganization plan.

According to the Seoul Bankruptcy Court and other sources on the 7th, approximately 2.4 million shares of Homeplus common stock held by MBK Partners through a special purpose company (SPC) were fully canceled without compensation as of September 14. This measure, included in the Homeplus reorganization plan approved by the court on September 2, was fully implemented in about two weeks.

MBK had previously explained that it had canceled shares worth 2.5 trillion won. However, the actual cancellation took place on September 14, after the reorganization plan was approved. It appears that MBK was only able to carry out the plan to cancel the common shares after the reorganization plan was approved.

Although MBK relinquished its status as a shareholder with the actual implementation of the cancellation, its relationship with Homeplus has not ended. According to industry sources, MBK and Chairman Kim Byung-ju have provided a joint and several guarantee for the full amount of the 200 billion won in emergency operating funds (DIP) loan provided by Meritz. They will continue to play a key role in the implementation of the reorganization plan, including the sale of assets from closed stores and the pursuit of corporate M&A. MBK explains that it has provided a total of 600 billion won in financial support through contributions of personal assets, cash injections, and guarantees.

Market observers view this share cancellation not merely as a fulfillment of responsibility but as a strategic move with future M&A in mind. With the existing major shareholders’ 2.5 trillion won worth of shares now completely eliminated, potential acquirers can consider a takeover without the legal and financial uncertainties associated with the equity structure. With the burden of acquiring existing shares removed, they are expected to be able to focus their resources solely on normalizing operations through the injection of new capital.

Homeplus is currently distributing teaser letters to major domestic and international companies in search of a new owner. It is reported that multiple candidates, including domestic and international strategic investors (SIs) and financial investors (FIs), are reviewing the acquisition. Samil Accounting Firm has been appointed as the advisor for the Homeplus sale.

Economy

Corporation

IT·Science

Economy

‘SMEC CO.,LTD Control Dispute’: SNT Holdings Demands Participation in Management Once Again

SNT Holdings, the largest shareholder currently in a dispute with SMEC CO.,LTD’s current management over control of the company, has proposed support for a capital increase while reiterating the need …
2026-10-07 18:20:34

Corporation

South Korea Enters the 160 Trillion Global Obesity Drug Market… HanmiGlobal Co., Ltd’s “Epe” Becomes First Domestically Developed Drug to Receive Approval

Epfeglenatide, developed by HanmiPharm, has received approval from the Ministry of Food and Drug Safety as the first domestically developed GLP-1-based obesity treatment. With this approval, Korea has…
2026-10-07 19:34:02

IT·Science

A Twist in the Story of the New Drug Rejected by Sanofi… Hanmi’s “Epe” Becomes the First Domestically Developed GLP-1 Weight-Loss Drug to Receive Approval

A new domestically developed drug has emerged to compete in the obesity treatment market, which is currently dominated by global pharmaceutical companies. With HanmiPharm’s efeglenatide receiving mark…
2026-10-07 18:22:02